Ready 8-Ks
3
Latest filing
June 17, 2026, 8:03 AM ET
Top materiality
0.55
Event mix
other_material ×2 · earnings ×1
Sentiment
1 pos · 0 neg · 2 neu
Recent 8-K filings for AVLN
Highest-materiality recent filing
Avalyn completes Phase 2b MIST trial enrollment of 375 patients for inhaled pirfenidone in PPF; topline data H2 2027
- Completed target enrollment of 375 patients in Phase 2b MIST trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis (PPF).
- Trial is randomized, double-blind, placebo-controlled, evaluating two doses (50 mg and 100 mg BID) vs placebo; primary endpoint is change in FVC at 52 weeks.
-
Completed target enrollment of 375 patients in Phase 2b MIST trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis (PPF).
-
Avalyn Pharma reports Q1 net loss of $26.9M; MIST Phase 2b enrollment on track
Net loss of $26.9M in Q1 2026 vs $17.5M in Q1 2025; R&D expense rose to $22.9M.
-
Avalyn Pharma adopts amended charter and bylaws upon IPO consummation
Authorizes 500M voting common shares and 200M non-voting common shares.
Materiality & sentiment trend
Max materiality 0.55 · Median 0.50 · Most common event other_material